SCHEMBL5541309

SCHEMBL5541309

COCCOc1cccc(Cl)c1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.49
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.35
KRAS P01116 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
TSHR P16473 2/20 0.34
HTR2A P28223 1/20 0.34
GRM2 Q14416 1/20 0.34
KEAP1 Q14145 1/20 0.34
TP53 P04637 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HTR1A P08908 1/20 0.34
SLC6A4 P31645 1/20 0.34
CYP2C19 P33261 2/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513738 0.89 HSD11B1 (0.52) HSD11B1ALDH1A1LMNAKMT2ATSHR
SCHEMBL4516365 0.88 HSD11B1 (0.54) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL4515325 0.86 HSD11B1 (0.49) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL4523062 0.85 HSD11B1 (0.48) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL4516411 0.84 HSD11B1 (0.47) HSD11B1LMNA
SCHEMBL4508316 0.84 HSD11B1 (0.49) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL3553955 0.83 HSD11B1 (0.64) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL4501877 0.81 HSD11B1 (0.44) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL4514002 0.80 HSD11B1 (0.60) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL2990265 0.79 HSD11B1 (0.59) HSD11B1ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885ALDH1A1 51/4885LMNA 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.